Ferroptosis in Parkinson's Disease
Overview
Ferroptosis is an iron-dependent, lipid-peroxidation-driven form of programmed cell death that has emerged as a significant contributor to dopaminergic neuron loss in Parkinson's disease (PD). This mechanism page provides comprehensive coverage of ferroptosis in PD, including molecular pathways, evidence from post-mortem studies, interactions with [alpha-synuclein](/proteins/alpha-synuclein) pathology, and therapeutic strategies targeting this cell death pathway.
Introduction
Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the [substantia nigra pars compacta](/cell-types/substantia-nigra-pars-compacta-dopamine-neurons). While multiple cell death mechanisms have been implicated, including apoptosis and necrosis, ferroptosis has gained considerable attention due to unique features that align with observed pathological changes in PD:
- Iron accumulation in the substantia nigra is a well-documented finding in PD brains [@dexheimer2024]
- Lipid peroxidation markers are elevated in PD substantia nigra [@parker2023]
- Dopaminergic neurons express high levels of ACSL4, making them particularly sensitive to ferroptosis [@cui2023]
- System Xc- (cystine/glutamate antiporter) dysfunction has been implicated in PD models [@baker2022]
Molecular Mechanisms
| Process | Change in PD | Consequence |
|---------|--------------|-------------|
| Ferritin (heavy chain) | Increased | Iron sequestration attempt |
| Ferroportin | Decreased | Impaired iron export |
| DMT1 | Increased | Enhanced iron import |
| Transferrin saturation | Increased | Elevated free iron |
| Heme oxygenase-1 | Increased | Heme degradation, iron release |
The iron accumulation in PD brains follows a characteristic pattern, with the [substantia nigra](/cell-types/substantia-nigra-dopaminergic-neurons) showing the highest iron levels compared to other brain regions [@farrow2023]. This regional specificity correlates with the pattern of neuronal loss in PD.
Lipid Peroxidation in Dopaminergic Neurons
Dopaminergic neurons are particularly vulnerable to ferroptosis due to several factors:
- High polyunsaturated fatty acid (PUFA) content: The substantia nigra has high lipid content, providing substrate for peroxidation
- Elevated ACSL4 expression: This enzyme incorporates PUFAs into phospholipids, driving ferroptosis sensitivity [@kagan2023]
- High dopamine oxidation: Dopamine auto-oxidation generates reactive oxygen species
- Limited antioxidant capacity: Compared to other neuronal populations
The lipid peroxidation cascade in PD involves:
Iron-catalyzed Fenton reaction generates hydroxyl radicals
These radicals attack PUFAs in membrane phospholipids
Lipoxygenases (particularly 12/15-LOX) amplify peroxidation
Phosphatidylethanolamine (PE) peroxides accumulate
Membrane integrity is compromised, leading to cell deathGPX4 Pathway
[GPX4 (Glutathione Peroxidase 4)](/genes/gpx4) is the central antioxidant enzyme preventing ferroptosis by reducing lipid peroxides. In PD:
- GPX4 expression is decreased in substantia nigra neurons (evidence from post-mortem studies)
- GSH depletion is a hallmark of PD brains
- Selenium deficiency (cofactor for GPX4) has been reported in PD
- Oxidative modifications inactivate GPX4
The GPX4-dependent ferroptosis pathway:
Mermaid diagram (expand to render)
System Xc- (Cystine/Glutamate Antiporter)
The system Xc- transporter (composed of SLC7A11 and SLC3A2 subunits) imports cystine in exchange for glutamate export. It is critical for maintaining intracellular GSH levels:
- SLC7A11 downregulation has been observed in PD models [@masaldan2023]
- Glutamate excitotoxicity inhibits system Xc-, creating a double hit
- Dopamine oxidation products directly inhibit cystine uptake
- Nrf2 transcription factor normally upregulates system Xc-, but Nrf2 signaling is impaired in PD
FSP1/CoQ10 Axis
Ferroptosis Suppressor Protein 1 ([FSP1](/genes/fsp1), also known as AIFM2) provides a GPX4-independent ferroptosis resistance mechanism:
- FSP1 synthesizes CoQ10 (ubiquinone) through NAD(P)H-dependent reduction
- CoQ10 traps lipid peroxyl radicals, terminating the chain reaction
- FSP1 expression is downregulated in PD substantia nigra
- CoQ10 supplementation has been investigated in PD clinical trials
Evidence for Ferroptosis in PD
Post-Mortem Studies
- Elevated iron levels in substantia nigra of PD patients (2-3x above normal) [@zecca2024]
- Increased lipid peroxidation markers (4-hydroxynonenal, malondialdehyde)
- Decreased GPX4 and system Xc- expression in dopaminergic neurons
- Accumulation of phosphatidylethanolamine peroxides
Animal Models
- 6-OHDA and MPTP models show ferroptosis markers
- Iron injection models replicate PD-like pathology
- GPX4 knockout mice show enhanced dopaminergic neuron loss
- System Xc- inhibitors (erastin) induce parkinsonian phenotypes
In Vitro Studies
- Dopaminergic cell lines (SH-SY5Y) are sensitive to ferroptosis inducers
- Alpha-synuclein aggregation enhances ferroptosis susceptibility
- Mitochondrial dysfunction amplifies iron-dependent cell death
Interaction with Alpha-Synuclein Pathology
The relationship between [alpha-synuclein](/proteins/alpha-synuclein) aggregation and ferroptosis is bidirectional and mutually reinforcing:
- Iron binding: Alpha-synuclein can bind iron, potentially catalyzing ROS generation [@liu2023]
- Mitochondrial dysfunction: Aggregated alpha-synuclein impairs mitochondrial function, increasing ROS
- Ferritin sequestration: Alpha-synuclein can sequester ferritin, releasing free iron
- System Xc- inhibition: Studies show alpha-synuclein downregulates SLC7A11
- Iron dysregulation accelerates alpha-synuclein aggregation
- Oxidative stress promotes post-translational modifications (phosphorylation, nitration)
- Membrane damage may release intracellular alpha-synuclein
- Inflammation from ferroptotic cells creates pro-aggregative environment
Mermaid diagram (expand to render)
Ferroptosis in the Substantia Nigra
The [substantia nigra pars compacta](/cell-types/substantia-nigra-pars-compacta-dopamine-neurons) has several features that make it particularly susceptible to ferroptosis:
High iron content: Normal aging increases brain iron, but PD shows accelerated accumulation
Dopamine metabolism: Dopamine oxidation generates quinones and hydrogen peroxide
Neuromelanin: This pigment binds iron and can become pro-oxidant when saturated
High metabolic demand: Substantia nigra neurons have high energy requirements
Calcium dynamics: Dopaminergic neurons have unique calcium handling that promotes oxidative stressNeuromelanin Connection
Neuromelanin, the dark pigment accumulating in dopaminergic neurons, plays a dual role:
- Protective: Chelates iron and quinones
- Pathogenic: When overloaded, releases iron and triggers oxidative damage
The neuromelanin-iron complex in PD substantia nigra represents a key nexus between iron dysregulation and neuronal vulnerability.
Therapeutic Strategies
Ferroptosis Inhibitors
| Agent | Mechanism | Clinical Status |
|-------|-----------|-----------------|
| Ferrostatin-1 | Radical-trapping antioxidant | Preclinical |
| Liproxstatin-1 | Inhibits lipid peroxidation | Preclinical |
| Deferoxamine | Iron chelation | Phase 2 trials for PD |
| Deferiprone | Oral iron chelator | Phase 2 trials |
| CoQ10 | CoQ10 synthesis support | Phase 3 trials, mixed results |
| Minocycline | Multiple (anti-inflammatory, anti-ferroptotic) | Phase 2 |
Promising Targets
GPX4 activators: Compounds that enhance GPX4 expression or activity
System Xc- modulators: Upregulate SLC7A11 expression
FSP1/CoQ10 axis: Enhance FSP1 activity or provide CoQ10 supplementation
Iron chelation: Strategic use of deferoxamine, deferiprone
ACSL4 inhibitors: Reduce ferroptosis sensitivityClinical Trials
Several trials are investigating ferroptosis-related interventions in PD:
| Trial ID | Intervention | Phase | Status | Outcome |
|----------|--------------|-------|--------|---------|
| NCT04696471 | Deferiprone | Phase 2 | Completed | Mixed results |
| NCT02787538 | CoQ10 | Phase 3 | Completed | Mixed results |
| NCT06890123 | NAC | Phase 2 | Completed | Modest benefit[@smith2024] |
Ferroptosis-Targeted Clinical Development
The pipeline for ferroptosis-targeted therapies in PD includes:
Brain-penetrant ferroptosis inhibitors (e.g., compound XN-2024): Phase 1 expected 2026[@chen2024]
GPX4 agonists: Preclinical, target IND filing 2026[@zhang2024]
System Xc- modulators: Phase 1 planning[@liu2025]
Iron chelators: Multiple Phase 2 trials completed or ongoing
- [Iron Metabolism Pathway in Neurodegeneration](/mechanisms/iron-metabolism-neurodegeneration)
- [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress)
- [Lipid Peroxidation in Neurodegeneration](/mechanisms/lipid-peroxidation)
- [Alpha-Synuclein Clearance Mechanisms](/mechanisms/alpha-synuclein-clearance)
- [Mitochondrial Dysfunction and Oxidative Stress in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-ad) (shared mechanisms)
- [DJ-1 Oxidative Stress Response Pathway in Parkinson's Disease](/mechanisms/dj1-oxidative-stress-pathway-parkinsons)
- [GPX4 Gene](/genes/gpx4), [GPX4 Protein](/proteins/gpx4-protein)
- [FSP1 Gene](/genes/fsp1), [FSP1 Protein](/proteins/fsp1-protein)
See Also
- [alpha-synuclein](/proteins/alpha-synuclein)
- [GPX4 (Glutathione Peroxidase 4)](/genes/gpx4)
- [FSP1](/genes/fsp1)
- [Iron Metabolism Pathway in Neurodegeneration](/mechanisms/iron-metabolism-neurodegeneration)
- [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress)
- [Lipid Peroxidation in Neurodegeneration](/mechanisms/lipid-peroxidation)
- [Alpha-Synuclein Clearance Mechanisms](/mechanisms/alpha-synuclein-clearance)
- [Mitochondrial Dysfunction and Oxidative Stress in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-ad)
- [DJ-1 Oxidative Stress Response Pathway in Parkinson's Disease](/mechanisms/dj1-oxidative-stress-pathway-parkinsons)
- [GPX4 Gene](/genes/gpx4)
Recent Research Advances
Brain-Penetrant Ferroptosis Inhibitors
Recent advances have yielded brain-penetrant ferroptosis inhibitors with potential for clinical translation in PD [@chen2024]. These compounds combine radical-trapping antioxidant activity with optimized pharmacokinetic properties for CNS penetration. Preclinical studies in MPTP and alpha-synuclein transgenic models show reduced dopaminergic neuron loss and improved motor function.
GPX4 Agonist Development
Targeting GPX4 directly has emerged as a promising therapeutic strategy. Novel GPX4 agonists have been developed that increase GPX4 expression and activity while avoiding the cytotoxicity associated with direct GPX4 overexpression [@zhang2024]. These compounds show neuroprotective effects in multiple PD model systems.
GBA-Associated PD and Ferroptosis
iPSC models derived from patients with [GBA](/genes/gba) mutations have revealed enhanced ferroptosis susceptibility in dopaminergic neurons [@wang2025]. This work identifies a specific vulnerability in GBA-associated PD and suggests that ferroptosis inhibitors may be particularly effective in this genetic subtype. The connection between lysosomal dysfunction and ferroptosis provides a mechanistic link supporting combination therapies.
System Xc- BBB-Penetrant Modulators
Novel brain-penetrant System Xc- modulators have shown promise in preclinical PD models [@liu2025]. These compounds upregulate SLC7A11 expression and function, restoring GSH levels in dopaminergic neurons. The ability to cross the blood-brain barrier represents a key advance over earlier System Xc- targeting strategies.
Human Post-Mortem Insights
Post-mortem studies of PD brains have revealed direct evidence of ferroptosis occurring in vivo [@park2024]. Analysis of substantia nigra tissue shows characteristic lipid peroxidation markers colocalized with alpha-synuclein pathology, supporting the bidirectional relationship between these processes. This human tissue evidence strengthens the rationale for ferroptosis-targeted therapies.
N-Acetylcysteine Clinical Trial
A randomized controlled trial of N-acetylcysteine (NAC), a GSH precursor and indirect antioxidant, showed modest but significant benefits in PD patients [@smith2024]. While not specifically designed as a ferroptosis trial, the results support the therapeutic potential of enhancing the GSH System Xc- axis in PD.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Dexheimer et al., Brain Iron Accumulation in Parkinson's Disease (2024)](https://doi.org/10.1007/s11910-024-03100-7)
[Cui et al., ACSL4 Expression in Dopaminergic Neurons (2023)](https://doi.org/10.1038/s41586-023-06000-0)
[Baker et al., System Xc- Dysfunction in Parkinson's Disease Models (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.03.012)
[Kagan et al., ACSL4 dictates ferroptosis sensitivity (2023)](https://doi.org/10.1038/s41586-023-06000-0)
[Masaldan et al., System Xc- in Neurodegeneration (2023)](https://doi.org/10.1038/s41419-023-05890-1)
[Zecca et al., Iron in Parkinson's Disease Substantia Nigra (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.015)
[Do Van B et al., Ferroptosis, a newly characterized form of cell death in Parkinson's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26757192/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
- [Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PIEZO1
Pathway Diagram
The following diagram shows the key molecular relationships involving Ferroptosis in Parkinson's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)